Login to Your Account

FDA Splits with Panel, Rejects Chelsea's NOH Drug Northera

By Jennifer Boggs
Managing Editor

Friday, March 30, 2012
Despite winning a reluctant yea vote from the Cardiovascular and Renal Drugs Advisory Committee last month, Chelsea Therapeutics International Inc.'s neurogenic orthostatic hypotension (NOH) candidate Northera (droxidopa) failed to win FDA approval, sending shares of the Charlotte, N.C.-based firm falling 28.6 percent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription